Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era

McNamara, Mairead G., Lwin, Zarnie, Jiang, Haiyan, Chung, Caroline, Millar, Barbara-Ann, Sahgal, Arjun, Laperriere, Normand and Mason, Warren P. (2014) Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era. Journal of Neuro-Oncology, 117 1: 153-160. doi:10.1007/s11060-014-1368-7


Author McNamara, Mairead G.
Lwin, Zarnie
Jiang, Haiyan
Chung, Caroline
Millar, Barbara-Ann
Sahgal, Arjun
Laperriere, Normand
Mason, Warren P.
Title Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era
Journal name Journal of Neuro-Oncology   Check publisher's open access policy
ISSN 0167-594X
1573-7373
Publication date 2014-03
Year available 2014
Sub-type Fully published paper
DOI 10.1007/s11060-014-1368-7
Open Access Status
Volume 117
Issue 1
Start page 153
End page 160
Total pages 8
Place of publication New York, NY, United States
Publisher Springer New York
Collection year 2015
Language eng
Formatted abstract
With standard treatment for glioblastoma (GBM) consisting of surgery followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ), median survival is ~14.6 months. This is not as informative to patients who have survived for some time. Conditional probability of survival may offer more relevant survival estimates. Outcomes/conditional probability of survival and post-progression survival (PPS) estimates were retrospectively reviewed in the TMZ treatment era of 882 consecutive patients with a diagnosis of GBM from January 2004 to August 2010. Median age of entire cohort was 62 years including 62 % males. Baseline performance status (PS) was 0–1 in 67, 23 % had frontal lobe tumors, 58 % received concurrent RT/TMZ ± adjuvant TMZ. Survival (OS) was similar for those with frontal lobe tumors versus other locations (P = 0.25). OS for patients receiving standard RT/TMZ ± TMZ was 14.2 months. Age, PS, extent of surgery, therapy post-surgery had significant effects on OS. OS for entire cohort at 1, 2, 3, 4, 5 years was 43.4, 17.9, 10.4, 8.4, 7.2 % respectively. Conditional probability of survival of an additional year given survival to 1, 2, 3, 4, 5 years was 41.4, 58, 80.7, 85.7, 81.5 % respectively. Conditional probability of survival for those patients receiving concurrent RT/TMZ ± adjuvant TMZ was similar. Patients who progress >18 months after their initial treatment for GBM had significantly greater 2 and 5 year PPS as well as OS. Conditional probabilities of survival may provide more meaningful life expectancy predictions for survivors of GBM than conventional survival outcomes.
Keyword Conditional probability of survival
Overall survival
Post-progression survival
Frontal lobe tumor
Glioblastoma
Temozolomide
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Fully published paper
Collections: Official 2015 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 30 Mar 2014, 00:13:04 EST by System User on behalf of Medicine - Royal Brisbane and Women's Hospital